Subsequent to our report[12], in vitro SCD1 inhibition experiments were conducted using small molecules for several cancers, such as lung cancer and breast cancer inhibited by N-(2-(6-(3,4-dichlorobenzylamino)-2-(4-​methoxyphenyl)-3-oxopyrido[2,3-b]pyrazin​-4(3H)-yl)ethyl)acetamide (CVT-11127) [56-58], pharyngeal cancer and lung cancer inhibited by 4-(2-chlorophenoxy)-N-(3-(3-methylcarbamoyl)phenyl)piperidine-1-carboxamide (A939572) [59], and colon cancer inhibited by 5-tetradecyloxy-2-furoic acid (TOFA) [60]. This evidence concerns the gene SCD and pharynx cancer.